Name: Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy by Foundation Fighting Blindness
Duration: 4 min 26 s
Description: Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

The Foundation funded earlier, proof-of-concept studies for the Best1 gene therapy and later launched Opus to develop several IRD gene therapies.

Opus Genetics Receives FDA Clearance to Launch Clinical Trial for Best1 Gene Therapy

September 5, 2025. Dr. George Magrath, CEO of Opus Genetics, talks with host Ben Shaberman about the company's evolution and progress in clinically developing gene therapies for several inherited retinal diseases including those caused by mutations in the genes: LCA5, BEST1, RHO, RDH12, MERTK, NMNAT1, and CNGB1.

Eye on the Cure Podcast | Episode 91: Dr. George Magrath

NACA is a gene-agnostic, oral medication designed to preserve vision in people with retinitis pigmentosa and Usher syndrome.

Nacuity’s Antioxidative Therapy NACA Performs Encouragingly in Phase 1/2 Clinical Trial

The documentary “Aggie: An Incredible Story of Art and Justice” chronicles her story.

Agnes Gund – Renowned Philanthropist, Social Justice Champion, and Art Patron – Passes Away

Lance Baldo, MD, CEO at Beacon Therapeutics, talks to host Ben Shaberman about his company's fully enrolled Phase 3 VISTA clinical trial for laru-zova, a gene therapy for X-linked retinitis pigmentosa (RPGR mutations) that's showed promising results in earlier trials. They also discuss Beacon's forthcoming clinical trial for its dry age-related macular degeneration gene therapy.

Eye on the Cure Podcast | Episode 92: Lance Baldo, MD

Durable vision improvements were also observed out to 18 months for previously dosed adult patients in the trial.

Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy

The emerging therapy improved vision for some participants in an earlier clinical trial.

Sepul Bio’s LCA10 RNA Therapy Moves into Phase 3 Clinical Trial

October 17, 2025. Sam Seavey, founder and host of the acclaimed The Blind Life YouTube channel, talks with host Ben Shaberman about his journey with Stargardt disease, some of the latest assistive technologies, and how the 900+ videos on The Blind Life can be informative and helpful for people with low vision.

Eye on the Cure Podcast | Episode 93: Sam Seavey

The approach may provide better visual acuity than current optogenetic therapies in clinical trials.

SparingVision Launches Clinical Trial for Therapy to Re-Activate Dormant Cones in Advanced RP

October 31, 2025. Dr. Victoria Claire has commissioned more than 200 sculptures, received an honorary doctorate, and is pursuing a PhD. She talks with host Ben Shaberman about her journey with retinitis pigmentosa, and how blindness has provided her with new and profound insights into herself and perceiving the world. Visitors to her current exhibition, "The Sense of Sculpture" (Oct. 18 - Nov. 1) at The Art House in Wakefield, England, are interacting with her sculptures tactilely in complete darkness.

Eye on the Cure Podcast | Episode 94: Dr. Victoria Claire

The Foundation Fighting Blindness is the driving force in the global development of treatments and cures for blinding diseases. To learn more, go to FightingBlindness.org.

Opus Reports Vision Improvements for Three Pediatric Patients in Phase 1/2 Clinical Trial for LCA5 Gene Therapy

Foundation Fighting Blindness

Related tracks